Literature DB >> 8840840

Significance of mild transient release of creatine kinase-MB fraction after percutaneous coronary interventions.

A E Abdelmeguid1, E J Topol, P L Whitlow, S K Sapp, S G Ellis.   

Abstract

BACKGROUND: The clinical significance of minor elevations in creatine kinase-myocardial band isoenzyme (CK-MB) after coronary interventions has not been systematically evaluated. METHODS AND
RESULTS: We examined 4484 patients who underwent successful percutaneous transluminal coronary angioplasty or directional coronary atherectomy and whose peak CK levels did not exceed twice the upper limit of laboratory normal. Group 1 (3776 patients) had no CK or MB elevation after the procedure (ie, CK < or = 180 IU/L, with MB fraction < or = 4%). Group 2 (450 patients) had a peak CK level between 100 and 180 IU/L, with MB fraction > 4%, and group 3 (258 patients) had a peak CK level between 181 and 360 IU/L, with MB fraction > 4%. The strongest correlate of postprocedure CK-MB elevation was the performance of directional coronary atherectomy (odds ratio, 4.1; P < .0001), followed by the development of > or = 1 in-1ab minor procedural complication (odds ratio, 2.6; P < .0001). Clinical follow-up was available in 4461 patients (99.5%), with a mean duration of 36 +/- 22 months. Survival analysis, adjusted with Cox proportional hazards regression model, showed that the groups with elevated CK-MB had a significantly higher incidence of cardiac death (risk ratio, 1.3; P = .04) and myocardial infarction (risk ratio, 1.3; P = .03). Major ischemic complications (death, myocardial infarction, and coronary revascularization) occurred more frequently in the groups with increased CK-MB (groups 1 versus 2 versus 3, 37.3% versus 43.3% versus 48.9%; P = .01).
CONCLUSIONS: This study shows that minor elevations of CK-MB after successful coronary interventions identify a population with a worse long-term prognosis compared with patients with no enzyme elevations and appear to have an adverse effect on long-term prognosis. Future studies of percutaneous coronary revascularization should include routine measurements of biochemical cardiac markers as important predictors of long-term prognosis.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8840840     DOI: 10.1161/01.cir.94.7.1528

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  32 in total

Review 1.  Clinical implications of the new definition of myocardial infarction.

Authors:  John K French; Harvey D White
Journal:  Heart       Date:  2004-01       Impact factor: 5.994

2.  Role of Akt/protein kinase B in the activity of transcriptional coactivator p300.

Authors:  J Chen; S S Halappanavar; J R St-Germain; B K Tsang; Q Li
Journal:  Cell Mol Life Sci       Date:  2004-07       Impact factor: 9.261

Review 3.  Statins and their role in pre-percutaneous coronary intervention.

Authors:  Rosetta Melfi; Annunziata Nusca; Giuseppe Patti; Germano Di Sciascio
Journal:  Curr Cardiol Rep       Date:  2010-07       Impact factor: 2.931

4.  Effects of lesion complexity on baseline and postprocedural B-type natriuretic peptide levels in patients undergoing percutaneous coronary interventions.

Authors:  Aylin Yildirir; Sadik Acikel; Cagatay Ertan; Alp Aydinalp; Bulent Ozin; Haldun Muderrisoglu
Journal:  Tex Heart Inst J       Date:  2007

Review 5.  Efficacy of short-term high-dose atorvastatin pretreatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a meta-analysis of nine randomized controlled trials.

Authors:  Yangchun Liu; Qiang Su; Lang Li
Journal:  Clin Cardiol       Date:  2013-08-27       Impact factor: 2.882

Review 6.  A risk-benefit assessment of abciximab in angioplasty.

Authors:  N S Kleiman
Journal:  Drug Saf       Date:  1999-01       Impact factor: 5.606

7.  Detection of coronary microembolisation by Doppler ultrasound during percutaneous coronary interventions.

Authors:  P Bahrmann; H R Figulla; M Wagner; M Ferrari; A Voss; G S Werner
Journal:  Heart       Date:  2005-09       Impact factor: 5.994

8.  Prognostic role of cardiac troponin I after percutaneous coronary intervention in stable coronary disease.

Authors:  T Nageh; R A Sherwood; B M Harris; M R Thomas
Journal:  Heart       Date:  2005-09       Impact factor: 5.994

9.  Impact of metabolic syndrome on myocardial injury and clinical outcome after percutaneous coronary intervention.

Authors:  J Li; S-J Song; J-P Xu; X-Z Zhao; Z-W Xu; X-J Sun; L-F Wang; X-C Yang
Journal:  Herz       Date:  2014-10-26       Impact factor: 1.443

10.  Baseline inflammation is not predictive of periprocedural troponin elevation after elective percutaneous coronary intervention.

Authors:  Olivier Gach; Olivier Louis; Jean Paul Chapelle; Sophie Vanbelle; Luc A Pierard; Victor Legrand
Journal:  Heart Vessels       Date:  2009-07-22       Impact factor: 2.037

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.